Biogen Inc. must now reckon with declining sales of drugs facing heavy competition and the risky odds of finding success in its pipeline, after giving up on the Alzheimer’s therapy that was supposed to propel it to new heights but instead crashed.
Adding to its challenges, the biotech will have to pull off a turnaround with new management, including a new chief executive to replace the CEO the company said Tuesday would leave.
